RxDoctor Payments Data

Andra Batlin, MD

Internal Medicine · Burlingame, CANPI 1801816343

Payments from drug & device makers

$2,368in general payments, 2019–2025

Across 118 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$356
  • Lilly USA, LLC$225
  • Novo Nordisk$155
  • Otsuka America Pharmaceutical, Inc.$153
  • Astellas Pharma US Inc$151
  • AbbVie$145
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,368 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$67,986
Medicare patients
166
Services billed
515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$15,367
Levothyroxine Sodium120$2,324
Atorvastatin Calcium162$1,570
SynthroidLevothyroxine Sodium16$993
Escitalopram Oxalate54$828
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide22$805
Simvastatin56$790
Famotidine21$750
Ezetimibe14$487
Omeprazole46$486
Rosuvastatin Calcium50$465
Albuterol Sulfate HfaAlbuterol Sulfate16$455
Lisinopril55$426
Metformin Hcl ErMetformin Hcl37$379
Metoprolol Succinate25$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$155$15,36716 claims
AbbVieSynthroid$145$99316 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$39$32612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →